SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Gilda Radner

PatientGilda Radner
Date of birth1986-06-28
IdentifiersMRN HR-ML026-SYN; SSN (made up) 000-26-8821
Document date2026-05-12
AuthorDelia Marchand, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review three weeks after cytoreductive surgery, on the first chemotherapy day. [S]

History of Present Illness

Ms. Radner returns three weeks after primary cytoreductive surgery: hysterectomy with removal of both tubes and ovaries, total omentectomy, stripping of the right diaphragm, and excision of pelvic nodules, with no visible disease left. She went home on the fifth day. The wound has healed. She is giving herself enoxaparin each evening and will finish the 28 days next week; she has had no bleeding or leg swelling. She needed acetaminophen for two weeks and nothing now. Her appetite is back and the bloating has gone. Since surgery she has hot flashes several times a day and night sweats. She came this morning for her first cycle of carboplatin and paclitaxel. She has had no thoughts of self-harm. [S]

ElementDetail
OperationComplete gross resection; home on day 5; wound healed
PathologyHigh-grade serous carcinoma of both ovaries, pT3c, FIGO stage IIIC; serous tubal intraepithelial carcinoma in the right tube
Genetic resultsGermline panel negative; tumor BRCA1 pathogenic variant; homologous recombination deficient
SymptomsBloating gone; appetite normal; new hot flashes and night sweats
MedicinesEnoxaparin, one week left; no pain medicine

Review of Systems

SystemResultFinding
ConstitutionalPositiveNight sweats with hot flashes; no fever; weight 55.2 kg
GastrointestinalNegativeNo bloating, nausea or vomiting; bowels normal
GenitourinaryNegativeNo urinary symptoms or vaginal bleeding
NeurologicalNegativeNo tingling or numbness in the hands or feet
CardiovascularNegativeNo calf pain or leg swelling
EndocrinePositiveHot flashes several times a day since surgery
PsychiatricNegativeMood fair; PHQ-9 5; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg under the skin once daily for 28 daysSubcutaneous route2026-04-21 to 2026-05-18completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-04-21 to 2026-05-05completedS
Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2026-05-12activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-12Body height160cmS
2026-05-12Body weight55.2kgS
2026-05-12Body mass index (BMI) [Ratio]21.6kg/m2S
2026-05-12Systolic blood pressure112mm[Hg]S
2026-05-12Diastolic blood pressure70mm[Hg]S
2026-05-12Heart rate84/minS
2026-05-12Respiratory rate14/minS
2026-05-12Body temperature36.7CelS
2026-05-12Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-12Hemoglobin [Mass/volume] in Blood10.9g/dL11.6-15 g/dLLowS
2026-05-12Leukocytes [#/volume] in Blood by Automated count6.910*3/uL4-11 10*3/uLNormalS
2026-05-12Neutrophils [#/volume] in Blood by Automated count4.210*3/uL1.5-7.7 10*3/uLNormalS
2026-05-12Platelets [#/volume] in Blood by Automated count35610*3/uL150-400 10*3/uLNormalS
2026-05-12Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.59-1.04 mg/dLNormalS
2026-05-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M114mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
2026-05-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
2026-05-12Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2026-05-12Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
2026-05-12Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.7-2.2 mg/dLNormalS
2026-05-12Cancer Ag 125 [Units/volume] in Serum or Plasma188U/mL<=35 U/mLHighS
2026-05-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-05-12Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S

Physical Exam

Vital signs recorded on 2026-05-12; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 112/70, pulse 84; weight 55.2 kg
AbdomenMidline incision healed without redness or hernia; soft, non-tender; no fluid
NeurologicalLight touch, pinprick and vibration normal in the hands and feet; ankle reflexes present (baseline before paclitaxel)
ExtremitiesNo calf tenderness or swelling; injection sites on the abdomen clean
PsychiatricEngaged and joking; organized

Problems

ProblemClinical statusVerificationCodeProvenance
Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the weekresolvedconfirmed R19.00S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation.
High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian canceractiveconfirmed C56.3S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D).
Peritoneal and omental metastases of the ovarian cancer, with ascitesactiveconfirmed C78.6S — Synthetic extent of disease on CT and biopsy.
Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is knownactiveconfirmed Z80.41S — Synthetic coding of her documented family history; the basis for genetic counseling.
Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweatsactiveconfirmed E89.41S — Synthetic consequence of the synthetic operation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySurgical pathology and stageAfter surgeryUp to dateHigh-grade serous carcinoma, pT3c, FIGO stage IIIC; no visible residual disease
LaboratoryGermline multigene panelOnce, at diagnosisCompleted todayReviewed with her: no pathogenic variant in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 or the Lynch syndrome genes
LaboratoryTumor testing for BRCA1 and BRCA2 and homologous recombination deficiencyOn the surgical specimen, before the maintenance decisionCompleted todayTumor BRCA1 pathogenic variant (somatic, as the germline test is negative); homologous recombination deficient
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore chemotherapyUp to dateAll negative; no antiviral prophylaxis needed
LaboratoryBlood count with neutrophils and plateletsBefore each chemotherapy cycleCompleted todayHemoglobin 10.9 g/dL after surgery, white cells 6.9, neutrophils 4.2, platelets 356
LaboratoryCreatinine and estimated kidney function (carboplatin dose)Before each cycleCompleted todayCreatinine 0.68 mg/dL, eGFR 114; carboplatin 610 mg for AUC 5
LaboratoryLiver tests (paclitaxel)Before each cycleCompleted todayALT 21, AST 20 U/L, bilirubin 0.4 mg/dL, albumin 3.7 g/dL
LaboratoryMagnesiumBefore each cycleCompleted today1.9 mg/dL
LaboratoryCA-125At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visitCompleted today188 U/mL, from 1240 before surgery
ExaminationPeripheral neuropathy: symptoms and examinationAt baseline and before each taxane cycleCompleted todayBaseline normal before the first paclitaxel dose
Medication safetyNausea and vomiting controlEach cycleCompleted todayThree-drug preventive regimen for carboplatin (an NK1 antagonist, a 5-HT3 antagonist and dexamethasone); ondansetron at home
Medication safetyPaclitaxel infusion reaction preventionEach paclitaxel doseCompleted todayDexamethasone, diphenhydramine and famotidine before the infusion; first-hour observation
Medication safetyThromboprophylaxis after cancer surgeryFrom surgery for four weeksCompleted todayDay 22 of 28 of enoxaparin; no bleeding or leg swelling
ExaminationWound reviewAfter surgeryCompleted todayHealed, without hernia
SurveyDistress and depression screen (PHQ-9)At diagnosis, at each treatment phase, and when symptoms changeCompleted todayPHQ-9 5; no thoughts of self-harm
SurveyPain scoreEach visit after surgeryCompleted todayWorst pain 2 of 10; no pain medicine
Self-managementMenopausal symptoms after oophorectomyEach visit after surgeryCompleted todayHot flashes several times a day and night sweats; non-hormonal measures
Self-managementPsychosocial support and informationAt diagnosis and throughoutCompleted todayJoined a cancer support community group last week

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(11):1222-1245 (2020); Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (2023); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Cycles every 21 days in the infusion center. Primary care and gynecologic oncology review at cycle 4. Call at once for a temperature of 38.0 °C or more. Next scheduled visit 2026-07-14: midpoint of chemotherapy: CA-125, blood counts, neuropathy, and menopausal symptoms. [S]